INTELLIA THERAPEUTICS

7.8800

14-May-25 16:45:00

15 minutes delayed

Stocks

-0.4400

-5.29%

Today's range

7.6500 - 8.5442

ISIN

N/A

Source

NASDAQ

Intellia Therapeutics Announces Second Quarter 2024 Financial Results and Highlights Recent Company Progress

08 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2024 Earnings and Company Updates

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Receives Authorization to Initiate Phase 1/2 Clinical Trial of NTLA-3001 for the Treatment of Alpha-1 Antitrypsin Deficiency

30 Jul 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

24 Jul 2024 16:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces CFO Transition

26 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Announces Positive Clinical Proof-of-Concept Data for Redosing a CRISPR-Based Therapy with its Proprietary LNP-Based Delivery Platform

25 Jun 2024 15:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Present the First-Ever Clinical Data From Patients Redosed with an Investigational In Vivo CRISPR Gene Editing Therapy at the Peripheral Nerve Society Annual Meeting 2024

17 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Names Brian Goff to its Board of Directors

14 Jun 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Positive Long-Term Data from Ongoing Phase 1 Study of NTLA-2002, an Investigational In Vivo CRISPR Gene Editing Treatment for Hereditary Angioedema (HAE)

02 Jun 2024 08:00:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Quarter 2024 Financial Results and Highlights Recent Company Progress

09 May 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2024 Earnings and Company Updates

02 May 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Present Updated Data from Phase 1/2 Study of NTLA-2002 for the Treatment of Hereditary Angioedema (HAE) at the EAACI Congress 2024

29 Apr 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces First Patient Dosed in the Phase 3 MAGNITUDE Study of NTLA-2001 as a Single-Dose CRISPR-Based Treatment for Transthyretin Amyloidosis with Cardiomyopathy

18 Mar 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2023 Financial Results and Highlights Recent Company Progress

22 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics and ReCode Therapeutics Announce Strategic Collaboration to Develop Novel Gene Editing Therapies for Cystic Fibrosis

15 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2023 Earnings and Company Updates

14 Feb 2024 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Publication of Positive Interim Phase 1 Data for NTLA-2002 in Patients with Hereditary Angioedema in the New England Journal of Medicine

31 Jan 2024 17:00:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Highlights its Three-Year Strategic Priorities and Anticipated 2024 Key Milestones

04 Jan 2024 16:01:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Receives European Union Orphan Drug Designation for NTLA-2002, an Investigational In Vivo CRISPR Genome Editing Treatment for Hereditary Angioedema

14 Nov 2023 07:30:00 By Nasdaq GlobeNewswire
Intellia Therapeutics Announces Third Quarter 2023 Financial Results and Highlights Recent Company Progress

09 Nov 2023 07:30:00 By Nasdaq GlobeNewswire

<<
<
1
2
3
4
>

I Agree NetDania's website uses cookies. By continuing browsing our website, you agree to our Cookie Policy, Privacy Policy and Terms and Conditons.